This update, in collaboration with CIDRAP at the University of Minnesota, delves into the ongoing complexities of US vaccine policy, drawing a parallel to the recurring attempts to fix a system that repeatedly falters.
The recent legal challenges, particularly concerning the Advisory Committee on Immunization Practices (ACIP), have created a vacuum. Despite attempts to reconfigure the ACIP’s charter and executive actions, the committee has been left without a quorum since a judicial stay was issued in March. This situation directly impacts the timely development of critical recommendations, such as those for fall respiratory vaccines, a point of concern for all involved.
A Pattern of Delays and Missed Deadlines
The government’s response to the court ruling has been characterized by a series of delays. A request for an expedited appeal, intended to address the urgent need for fall vaccine recommendations, has been met with a briefing schedule that extends beyond crucial ordering timelines. This raises questions about the urgency claimed, particularly since the fall respiratory season occurs predictably each year. Furthermore, the ACIP’s scheduled June meeting was canceled due to the ongoing litigation, despite insurers having already committed to covering recommended vaccines.
COVID-19 Vaccine Decisions in Limbo
The lack of a functioning ACIP has also stalled progress on the upcoming COVID-19 vaccine formulation. Following the FDA’s recommendation for the XFG strain for the fall 2026-27 season, the ACIP’s endorsement is the standard next step for official recommendations and cost coverage. Meanwhile, significant federal contracts have been awarded for COVID-19 vaccines, although the framing of these contracts as potential purchases versus readiness agreements remains a point of discussion. Concerns have been raised about the administration of these vaccines through programs like Vaccines for Children without a current ACIP recommendation, though prior approvals may negate this issue.
Flu Vaccine Developments and Unforeseen Challenges
A recent development involves a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) for Moderna’s mRNA influenza vaccine for adults aged 50 and older. This marks a significant step for a product that faced an earlier review reversal. However, the final decision on its availability for the upcoming respiratory season hinges on both FDA approval and ACIP recommendations, highlighting the ongoing reliance on the committee. This situation is underscored by a recent flu outbreak among recruits at Lackland Air Force Base, where a reinstatement of the flu vaccine mandate followed a decline in vaccination rates after it became optional.
Legislative Moves and Misinformation
State legislative sessions have seen a concerning trend of bills introduced that aim to link vaccines to sudden infant and child deaths. These bills, often using recycled language, propose requiring vaccination history on autopsy reports for unexplained infant and child deaths. While signed into law in Oklahoma and Louisiana, similar proposals have stalled or been vetoed in other states. These legislative efforts are rooted in the unsubstantiated claim that vaccines cause SUID, a position often supported by misinterpretations of the Vaccine Adverse Event Reporting System (VAERS). Scientific studies, conversely, show no association or a slightly reduced risk of SUID among vaccinated children.
Other Developments of Note
- COVID-19 vaccine effectiveness confirmed: A CDC study published in JAMA Network Open reinforces the effectiveness of updated COVID-19 vaccines, showing they can halve the risk of emergency department visits or hospitalizations in healthy adults.
- New candidate for FDA head: Dr. Heidi Overton is reportedly a finalist for the permanent FDA commissioner position, following the departure of Marty Makary.
- Inquiry into HHS vaccine policy: Senate Finance Committee Democrats have initiated an inquiry into the overhaul of the ACIP, seeking documentation on the process and decision-making.
- Proposed changes to federal grant oversight: The Office of Management and Budget has proposed a significant revision to federal grant oversight, impacting how research is funded and conducted. Public comments are being accepted until July 13.
The persistent challenges in vaccine policy underscore the need for continued scrutiny. The current landscape suggests that while immediate fixes are attempted, the underlying issues remain until they are fully addressed. Readers with questions about vaccines and vaccine policy are encouraged to submit them to vaccines@unbiasedscience.com, as these inquiries directly shape future coverage.